Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$45.42 USD

45.42
847,455

-0.09 (-0.20%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $45.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Globus Medical Sees Strong Rebound Despite Coronavirus Crisis

by Zacks Equity Research

Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.

Nalak Das headshot

7 Top-Ranked Corporate Giants With More Than 50% Return YTD

by Nalak Das

A handful of corporate giants (market capital > $10 billion) have skyrocketed this year, braving the pandemic and its impact on businesses.

QIAGEN Launches Primer Panel for NGS of Coronavirus Genome

by Zacks Equity Research

QIAGEN (QGEN) expands the NGS portfolio with the launch of the genome analyzing panel to support holistic research of the SARS-CoV-2.

Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (QGEN) Outperforming Other Medical Stocks This Year?

Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking

by Zacks Equity Research

Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.

Urmimala Biswas headshot

Will Thermo Fisher's (TMO) Failed QIAGEN Deal Cost it a Lot?

by Urmimala Biswas

The COVID-19 tailwinds are significantly stronger than what Thermo Fisher (TMO) had originally expected in March.

Boston Scientific's Voraxaze's MAA Accepted by EMA for Review

by Zacks Equity Research

Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be upbeat about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes

by Zacks Equity Research

Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.

EPA Validates NEOGEN's Disinfectant for Use Against COVID-19

by Zacks Equity Research

NEOGEN's (NEOG) BioSentry 904 Disinfectant approved by the EPA for use against the COVID-19-causing SARS-CoV-2 virus.

Omnicell, Pharmaceutical Strategies Enter Acquisition Deal

by Zacks Equity Research

Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.

Medtronic (MDT) Plans $160 Million R&D Investment in India

by Zacks Equity Research

The newest expansion plan of MEIC will help Medtronic (MDT) advance in the field of pain alleviation and restoration of health.

Medtronic Plans New Acquisition in AI-Driven Diabetes Care

by Zacks Equity Research

Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.

QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up

by Zacks Equity Research

QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.

Is a Surprise Coming for QIAGEN (QGEN) This Earnings Season?

by Zacks Equity Research

QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Canopy Growth (CGC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

Orthofix JuniOrtho Plating System Gets Regulatory Clearances

by Zacks Equity Research

Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.

Amedisys Rides on Coronavirus-Led Business Amid Cost Woes

by Zacks Equity Research

Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.

Quest Diagnostics Gets EUA for Coronavirus Sample Pool Testing

by Zacks Equity Research

Quest Diagnostics (DGX) is riding high on a slew of EUAs for the expanded use of its self-collection molecular diagnostic kit on different platforms.

Rising Coronavirus Cases Spark Lockdown Fears: 5 Defensive Picks

by Zacks Equity Research

Given the current coronavirus scenario, investors can invest in defensive stocks that can return well even during phases of market volatility

Medtronic Banks on Ventilator Sales Amid Coronavirus Crisis

by Zacks Equity Research

Medtronic (MDT) is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, it demonstrates a strong solvency position.

Integra Reports Organic Sales Drop in Preliminary Q2 Results

by Zacks Equity Research

Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.

Zacks.com featured highlights include: Laboratory Corporation of America, SpartanNash Company, B&G Foods, QIAGEN and Rent-A-Center

by Zacks Equity Research

Zacks.com featured highlights include: Laboratory Corporation of America, SpartanNash Company, B&G Foods, QIAGEN and Rent-A-Center